| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of Pathology [L. C. Y., B. G. C., S. P. C. C., R. G. D.] and Oncology [B. G. C., S. P. C. C., R. G. D.], and Cancer Research Laboratories [L. C. Y., B. G. C., S. P. C. C., R. G. D., J. H. G.], Queen’s University, Kingston, Ontario, K7L 3N6 Canada
Previously (L. C. Young et al., Clin. Cancer Res., 5: 673–680, 1999), we found, in a panel of 23 lung cancer cell lines that had not been selected for in vitro drug resistance, that the mRNA levels of MRP3 and MRP1, two members of the ATP-binding cassette superfamily of transport proteins, correlated with resistance to doxorubicin, vincristine, VP-16, and cis-diamminedicholoroplatinum(II). To extend these studies, we measured multidrug resistance protein (MRP)1, MRP2, and MRP3 protein levels in a panel of 30 lung cancer cell lines that included the original 23 cell lines as well as an additional 7 unselected lung cancer cell lines. In the case of MRP3, a polyclonal antibody was developed that was found to be a sensitive reagent for the detection of MRP3 by Western blot analysis. We found good agreement in the original 23 cell lines between the cognate mRNA and protein levels for MRP1, MRP2, and, especially, MRP3 (r, 0.852), supporting the use of semiquantitative PCR to predict MRP1, MRP2, and MRP3 protein levels in patient samples. There were also strong correlations between the mRNA and protein levels of MRP3 and MRP1, which suggested that these genes might be expressed in a coordinate manner. MRP3, MRP1, and MRP2 protein levels were higher in the non-small cell lung cancer (NSCLC) than in the SCLC cell lines and, in addition, MRP3 and MRP2 were detected almost exclusively in the NSCLC cell lines. Finally, we found that both MRP3 and MRP1, but not MRP2, protein levels correlated with decreased sensitivity of these lung cancer cell lines to doxorubicin, VCR, VP-16, and cis-diamminedicholoroplatinum(II). These findings are consistent with our hypothesis that both MRP3 and MRP1 are components of the multifactorial multidrug resistance phenotype of lung cancer and that MRP3 contributes to the intrinsic resistance of NSCLC cells.
This article has been cited by other articles:
|
|
 |
|
  S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, et al. Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3423 - 3432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fischer, N. Taylor, S. Allerstorfer, M. Grusch, G. Sonvilla, K. Holzmann, U. Setinek, L. Elbling, H. Cantonati, B. Grasl-Kraupp, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition Mol. Cancer Ther., October 1, 2008; 7(10): 3408 - 3419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Kim, P. N. Bogner, N. Ramnath, Y. Park, J. Yu, and Y.-M. Park Elevated Peroxiredoxin 1, but not NF-E2-Related Factor 2, Is an Independent Prognostic Factor for Disease Recurrence and Reduced Survival in Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3875 - 3882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lindenmaier, M. Becker, W. E. Haefeli, and J. Weiss INTERACTION OF PROGESTINS WITH THE HUMAN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2) Drug Metab. Dispos., November 1, 2005; 33(11): 1576 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Kang, E. Lee, H. Pyo, and S.-J. Lim Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells Mol. Cancer Ther., September 1, 2005; 4(9): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Gillet, T. Efferth, D. Steinbach, J. Hamels, F. de Longueville, V. Bertholet, and J. Remacle Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes Cancer Res., December 15, 2004; 64(24): 8987 - 8993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Tian, M. J. Zamek-Gliszczynski, P. Zhang, and K. L. R. Brouwer Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes Mol. Pharmacol., October 1, 2004; 66(4): 1004 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Loganzo, M. Hari, T. Annable, X. Tan, D. B. Morilla, S. Musto, A. Zask, J. Kaplan, A. A. Minnick Jr., M. K. May, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in {alpha}-tubulin Mol. Cancer Ther., October 1, 2004; 3(10): 1319 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, K. Goto, Y. Nishiwaki, T. Kodama, M. Suga, and A. Ochiai Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Steinbach, S. Wittig, G. Cario, S. Viehmann, A. Mueller, B. Gruhn, R. Haefer, F. Zintl, and A. Sauerbrey The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype Blood, December 15, 2003; 102(13): 4493 - 4498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-W. Zhang, H.-M. Gu, D. Situ, A. Haimeur, S. P. C. Cole, and R. G. Deeley Functional Importance of Polar and Charged Amino Acid Residues in Transmembrane Helix 14 of Multidrug Resistance Protein 1 (MRP1/ABCC1): IDENTIFICATION OF AN ASPARTATE RESIDUE CRITICAL FOR CONVERSION FROM A HIGH TO LOW AFFINITY SUBSTRATE BINDING STATE J. Biol. Chem., November 14, 2003; 278(46): 46052 - 46063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, J. Tsurutani, Y. Nakamura, S. Doi, T. Kitazaki, K. Sugahara, et al. Expression and Functional Analyses of Breast Cancer Resistance Protein in Lung Cancer Clin. Cancer Res., August 1, 2003; 9(8): 3052 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steinbach, J. Lengemann, A. Voigt, J. Hermann, F. Zintl, and A. Sauerbrey Response to Chemotherapy and Expression of the Genes Encoding the Multidrug Resistance-associated Proteins MRP2, MRP3, MRP4, MRP5, and SMRP in Childhood Acute Myeloid Leukemia Clin. Cancer Res., March 1, 2003; 9(3): 1083 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohishi, Y. Oda, T. Uchiumi, H. Kobayashi, T. Hirakawa, S. Miyamoto, N. Kinukawa, H. Nakano, M. Kuwano, and M. Tsuneyoshi ATP-binding Cassette Superfamily Transporter Gene Expression in Human Primary Ovarian Carcinoma Clin. Cancer Res., December 1, 2002; 8(12): 3767 - 3775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. N. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J. M. Sanchez, P. H. Gumerlock, M. Taron, et al. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2002; 8(7): 2286 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zelcer, T. Saeki, G. Reid, J. H. Beijnen, and P. Borst Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3) J. Biol. Chem., November 30, 2001; 276(49): 46400 - 46407. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
